Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases Pharmaceutical Investing
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo Plus Yervoy as Adjuvant Treatment of Localized Renal Cell Carcinoma Pharmaceutical Investing
RINVOQ® Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis Pharmaceutical Investing
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation Pharmaceutical Investing
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection Pharmaceutical Investing
Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9 Pharmaceutical Investing
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Crohn's Disease Pharmaceutical Investing
